Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Amortization of Deferred Charges (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Amortization of Deferred Charges for 6 consecutive years, with $873000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortization of Deferred Charges rose 9.13% year-over-year to $873000.0, compared with a TTM value of $3.4 million through Dec 2025, up 12.43%, and an annual FY2025 reading of $3.4 million, up 12.43% over the prior year.
  • Amortization of Deferred Charges was $873000.0 for Q4 2025 at Xeris Biopharma Holdings, up from $800000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $900000.0 in Q2 2025 and bottomed at $219000.0 in Q1 2022.
  • Average Amortization of Deferred Charges over 5 years is $557900.0, with a median of $550000.0 recorded in 2022.
  • The sharpest move saw Amortization of Deferred Charges dropped 12.75% in 2022, then surged 128.31% in 2023.
  • Year by year, Amortization of Deferred Charges stood at $273000.0 in 2021, then soared by 68.13% to $459000.0 in 2022, then rose by 8.93% to $500000.0 in 2023, then surged by 60.0% to $800000.0 in 2024, then increased by 9.12% to $873000.0 in 2025.
  • Business Quant data shows Amortization of Deferred Charges for XERS at $873000.0 in Q4 2025, $800000.0 in Q3 2025, and $900000.0 in Q2 2025.